126 related articles for article (PubMed ID: 20101735)
1. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
Huynh H
Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735
[TBL] [Abstract][Full Text] [Related]
2. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
4. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
5. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
6. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.
Piguet AC; Semela D; Keogh A; Wilkens L; Stroka D; Stoupis C; St-Pierre MV; Dufour JF
J Hepatol; 2008 Jul; 49(1):78-87. PubMed ID: 18486258
[TBL] [Abstract][Full Text] [Related]
8. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
9. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
10. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
[TBL] [Abstract][Full Text] [Related]
11. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.
Semela D; Piguet AC; Kolev M; Schmitter K; Hlushchuk R; Djonov V; Stoupis C; Dufour JF
J Hepatol; 2007 May; 46(5):840-8. PubMed ID: 17321636
[TBL] [Abstract][Full Text] [Related]
12. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.
Schad K; Baumann Conzett K; Zipser MC; Enderlin V; Kamarashev J; French LE; Dummer R
Clin Cancer Res; 2010 Feb; 16(3):1058-64. PubMed ID: 20103661
[TBL] [Abstract][Full Text] [Related]
13. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
McDaid HM; Lopez-Barcons L; Grossman A; Lia M; Keller S; Pérez-Soler R; Horwitz SB
Cancer Res; 2005 Apr; 65(7):2854-60. PubMed ID: 15805287
[TBL] [Abstract][Full Text] [Related]
15. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M
Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.
Huynh H; Soo KC; Chow PK; Tran E
Mol Cancer Ther; 2007 Jan; 6(1):138-46. PubMed ID: 17237274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
